GlassScriptPhysician profile
Zaki A Samman
NPI 1841295383
$9,115.71
in general payments reported to CMS, 2019-2025
53 companies · $1,904 in 2025
The $1,904 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,542 · 2020: $280 · 2021: $28.11 · 2022: $1,378 · 2023: $2,069 · 2024: $1,915 · 2025: $1,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,749 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,748.93 |
| Education | $139.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $938.26 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $676.65 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $596.53 | 2019-2025 | Venclexta |
| Daiichi Sankyo INC. | $552.05 | 2019-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $547.95 | 2019-2025 | |
| Pfizer INC. | $546.78 | 2019-2025 | |
| Eisai INC. | $496.76 | 2019-2025 | |
| Glaxosmithkline, LLC. | $492.23 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Janssen Biotech, INC. | $377.16 | 2019-2025 | Rybrevant, Darzalex, Erleada |
| Amgen INC. | $358.40 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $309.66 | 2019-2025 | Opdivo, Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $271.02 | 2019-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $253.64 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Beigene USA, INC. | $224.69 | 2023-2024 | Brukinsa |
| Gilead Sciences, INC. | $220.47 | 2019-2025 | Trodelvy |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $219.12 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Seagen INC. | $200.12 | 2019-2023 | Tukysa, Adcetris |
| Kite Pharma, INC. | $151.72 | 2020-2023 | Yescarta |
| Exelixis INC. | $143.79 | 2019-2024 | Cabometyx |
| Incyte Corporation | $130.95 | 2023-2025 | Monjuvi, Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $120.49 | 2019-2025 | |
| Genzyme Corporation | $100.80 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $93.37 | 2022-2024 | Libtayo |
| Emd Serono, INC. | $85.25 | 2022-2025 | Bavencio |
| Aveo Pharmaceuticals, INC. | $85.22 | 2023-2025 | Fotivda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.06 | 2019-2023 | Gilotrif |
| Takeda Pharmaceuticals U.S.A., INC. | $74.55 | 2022-2025 | Fruzaqla, Ninlaro |
| Rigel Pharmaceuticals, INC. | $74.33 | 2019-2024 | Rezlidhia, Tavalisse |
| Puma Biotechnology, INC. | $52.83 | 2019-2024 | |
| Pharmaessentia USA Corporation | $50.60 | 2023-2025 | Besremi |
| Foundation Medicine, INC. | $47.51 | 2019 | |
| Astellas Pharma US INC | $46.49 | 2019-2025 | Vyloy |
| Sumitomo Pharma America, INC. | $42.64 | 2024 | Orgovyx |
| Genentech USA, INC. | $40.59 | 2019-2023 | Tecentriq |
| Stemline Therapeutics INC. | $39.75 | 2024-2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $36.32 | 2019-2024 | |
| Tempus Ai, INC | $34.43 | 2024-2025 | Xt Cdx |
| Ipsen Biopharmaceuticals, INC | $31.05 | 2023 | Onivyde, Somatuline Depot |
| Geron Corporation | $29.33 | 2024-2025 | Rytelo |
| Janssen Pharmaceuticals, INC | $25.38 | 2022-2023 | Xarelto |
| Alexion Pharmaceuticals, INC. | $20.92 | 2024 | Ultomiris |
| Adaptive Biotechnologies Corporation | $20.66 | 2023 | Clonoseq |
| Sobi, INC | $19.98 | 2024 | |
| Morphosys, US INC. | $18.35 | 2023 | Monjuvi |
| Cti Biopharma Corp. | $16.85 | 2022 | |
| Grifols USA, LLC | $15.70 | 2019 | |
| Kyowa Kirin, INC. | $15.53 | 2022 | |
| Pharmacosmos Therapeutics INC. | $15.47 | 2024 | Cosela |
| Array Biopharma INC | $14.76 | 2024 | Braftovi, Lorbrena, Mektovi |
| Tolmar, INC. | $14.33 | 2024 | |
| Mirati Therapeutics, INC. | $14.00 | 2023 | Krazati |
| Epizyme, INC. | $13.84 | 2022 | |
| G1 Therapeutics, INC. | $13.38 | 2023 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zaki Samman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.